US FDA criticises medical practice efficiency claims in Eligard promotion
This article was originally published in Scrip
Executive Summary
A Sanofi-Aventis promotion for the advanced prostate cancer treatment Eligard (leuprolide acetate for injectable suspension) presents unsubstantiated claims that the twice-yearly dosing schedule will make healthcare practices more efficient, the US FDA has said.